Print this page

Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.

Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.

Before prescribing FLOMAX, please see the full Prescribing Information.

1. AUA Practice Guidelines Committee. Diagnosis and treatment recommendations.: AUA guideline on management of benign prostatic hyperplasia (2003). J Urol. 2003;170:530-547.

2. Dobrovits M, Chaudry A, Anagnostou T, et al. A longitudinal prospective study of men with mild symptoms of BOO treated with watchful waiting over 4 years. Eur Urol Suppl. 2003;2(1):26.

3. Jiménez-Cruz F. Identifying patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl. 2003;2(7):6-12.

4. Coffey DS. Controversies in the management of lower urinary tract symptoms: an overview. Br J Urol. 1998;81(suppl 1):1-5.

5. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.

6. Center for Food Safety and Applied Nutrition, US Food and Drug Administration. Letter, May 26, 2000.

7. Beduschi R, et al. Geriatrics. 1998; 53: 24-40.

Terms of Use | Privacy Policy | Contact Us | Site Map | Print This Page | Home
Boehringer Ingelheim - astellas The information provided on this site is intended only for healthcare professionals licensed and practicing in the United States.